ABC | Volume 110, Nº6, June 2018

Original Article Reis et al Hypertrophic Cardiomyopathy Arq Bras Cardiol. 2018; 110(6):524-531 1. Elliot PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy - The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. 2. Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013;381(9862):242-55. 3. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287(10):1308-20. 4. MaronBJ,MaronMS,SemsarianC.Geneticsofhypertrophiccardiomyopathy after 20 years: clinical perspectives. J AmColl Cardiol. 2012;60(8):705-15. 5. CardimN, Freitas A, BritoD. Fromhypertrophic cardiomyopathy centers to inherited cardiovascular disease centers in Europe. A small or a major step? A position paper from the Nucleus of the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology. Rev Port Cardiol. 2011;30(11):829-35. 6. Monteiro S, Costa S, Monteiro P, Gonçalves L, Providência LA. Hypertrophic cardiomyopathy--stateoftheartin2007.RevPortCardiol.2008;27(5):625-37. 7. Efthimiadis GK, Zegkos T, Meditskou S, Hadjimiltiades S. Perspectives on sudden death prevention in hypertrophic cardiomyopathy. Cardiol Rev. 2014;22(5):210-6. 8. Magnusson P, Gadler F, Liv P, Mörner S. Risk markers and appropriate implantable defibrillator therapy in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2016;39(3):291-301. 9. Vriesendorp PA, Schinkel AF, Van Cleemput JV, Willems R, Jordaens LJ, Theuns DA, et al. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: Patients outcomes, rate of appropriate and inappropriate interventions, and complications. AmHeart J. 2013;166(3):496-502. 10. GershBJ,MaronBJ,BonowRO,DearaniJA,FiferMA,LinkMS,etal;American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA Guideline for the Diagnosis and TreatmentofHypertrophicCardiomyopathy-AReportoftheAmericanCollege of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J AmColl Cardiol. 2011;58(25):e212-60. 11. O’Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013 Apr;99(8):534-41. 12. Beadle R, Williams L. Device therapy in hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther. 2010;8(12):1767-75. 13. Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, Ten Cate FJ, et al. Validaton of the 2014 European Society of Cardiology Guidelines risk prediction model for the primary prevention of sudden cardiacdeath inhypertrophiccardiomyopathy.CircArrhythmElectrophysiol. 2015;8(4):829-35. 14. MaronBJ,CaseySA,ChanRH,GarberichRF,RowinEJ,MaronMS.Independent assessment of the European Society of Cardiology sudden death riskmodel for hypertrophic cardiomyopathy. AmHeart J. 2015;116(5):757-64. 15. O’Mahony C, Jichi F, PavlouM, Monserrat L, Anastasakis A, Rapezzi C, et al; Hypertrophic CardiomyopathyOutcomes Investigators. A novel clinical risk predictionmodel for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J. 2014;35(30):2010-20. 16. Kelley-Hedgepeth A, Maron MS. Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy. Curr Heart Fail Rep. 2009;6(3):135-41. 17. Maron BJ. Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation. 2010;121(3):445-56. 18. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, et al. Efficacy of implantable cardioverter–defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342(6):365-73. 19. Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta- analysis. Circ Heart Fail. 2012;5(5):552-9. 20. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, et al. Prevention of sudden cardiac death with implantable cardioverter- defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61(14):1527-35. 21. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J AmColl Cardiol. 2014;64(1):83- 99. Erratum in: J Am Coll Cardiol. 2014;64(11):1188. 22. Maron BJ, Rowin EJ, Casey SA, LinkMS, Lesser JR, Chan RH, et al. Hypertrophic cardiomyopathyassociatedwithlowcardiovascularmortalitywithcontemporary managementstrategies.JAmCollCardiol.2015;65(18):1915-28. 23. Spirito P, Autore C, Rapezzi C, Bernabò P, Badagliacca R, Maron MS, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009;119(13):1085-92. 24. Bos JM, Maron BJ, Ackerman MJ, Haas TS, Sorajja P, Nishimura RA, et al. Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;106(10):1481-6. 25. Elliot PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36(7):2212-8. 26. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, et al. Prevention of sudden cardiac death with implantable cardioverter- defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61(14):1527-35. References Study Association This study is not associatedwith any thesis or dissertationwork. Ethics approval and consent to participate This study was approved by the Ethics Committee Comissão Nacional de Proteção de Dados (CNPD) under the protocol number 6416/ 2018. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 530